Arca
Skip to content
Tools
Tools

Dilated cardiomyopathy

Drug research and approvals for dilated cardiomyopathy: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 22, 2026, 56 studies of dilated cardiomyopathy are recruiting on ClinicalTrials.gov, Health Canada has authorized 2 drug trials for it since 2013, and FDA has 1 approved and 3 open orphan designations naming it.

  • Recruiting worldwide: 56
  • Trials authorized in Canada: 2
  • FDA orphan approvals: 1
  • EU medicines: 0

Recruiting now

Newest posted first, of 56 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Phase 3 6

Phase 2 7

How its trials ended

238 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 41 whose ending is known, 34% met their primary endpoint, 5% missed it and 61% stopped early.

  • Completed, result not reported7833%
  • Ongoing6527%
  • Status unknown5423%
  • Met its primary endpoint146%
  • Stopped: other or unclear146%
  • Stopped: sponsor or business decision52%
  • Stopped: enrollment or feasibility42%
  • Missed its primary endpoint21%
  • Stopped: safety1<1%
  • Stopped: funding1<1%

Trials authorized in Canada

Newest first; search them all in Canada trials
May 25, 2018A phase 3, multinational, randomized, placebo-controlled study of ARRY-371797 in patients with symptomatic dilated cardiomyopathy due to a lamin a/c gene…ARRY-371797 (PF-07265803)PfizerOngoing
Sep 13, 2013"a multicentre, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy, safety and tolerability of transendocardial…Ixmyelocel-tAastrom Biosciences, Inc.Pending

FDA orphan designations

Approved first, then open designations, newest first
Apr 22, 2019CorlanorCorlanor is indicated for the treatment of stable symptomatic heart failure due to dilated cardiomyopathy (DCM) in pediatric patients aged…Amgen, Inc.,Approved
Jul 16, 2026A non-replication recombinant adeno-associated virus (AAV)…Treatment of dilated cardiomyopathy due to mutations in the BAG3 geneAffinia TherapeuticsDesignated
Oct 30, 2018TrimetazidineTreatment of dilated cardiomyopathyMartin Pharmaceuticals, Inc.Designated
Nov 19, 2015VasomeraTreatment of cardiomyopathy associated with dystrophinopathies; Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy BMD), and…ImmunoForge Co. Ltd.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.